Leading provider of renal and hospital products cum services, Baxter International, Inc. (BAX - Free Report) , announced that its Sigma Spectrum Infusion System was nominated as the best-in-class by a report of the KLAS research firm.
In the Medical Equipment report, the Sigma Spectrum Infusion System was named as best for Smart Pumps – Large Volume Pumps. This is the fifth best KLAS award for Sigma Spectrum. The award is based on feedback from end users as well as opinion of hospital executives and managers who make purchasing decisions.
We are bullish on the recognition as it implies that Sigma Spectrum outperformed the other smart pumps in the market. It also indicates a high level of customer satisfaction with the platform and its support services. Also recently, Sigma Spectrum was recognized by KLAS in another report ''Smart Pumps 2016: The Quest for Patient Safety'' as a leader in drug library compliance and overall ease of use.
Of late, Baxter has been gaining ground on a series of notable developments which include the tie-up with Satellite Healthcare (the sixth-largest provider of kidney disease services in the U.S.) and the recognition of its Sigma Spectrum Infusion System as a highly efficient infusion pump in drug library compliance (analysis by KLAS research firm).
Also, based on the company’s strong performance in the first three quarters of the year, Baxter recently raised its outlook for the full year. Baxter now expects sales to increase approximately 2% on a reported basis and 4% at cc. The previous sales guidance for reported basis was in the range of 1% to 2% and at cc in the range of 3% to 4%. Adjusted earnings per share are now anticipated in the range of $1.88 to $1.91, up from the earlier guidance of $1.69 to $1.74. For the fourth quarter of 2016, Baxter expects sales growth at both reported and cc of approximately 2%. Adjusted earnings are forecast in the range of 49 cents to 52 cents per share.
Zacks Rank & Key Picks
Baxter International currently carries a Zacks Rank #1 (Strong Buy). Other medical stocks worth considering include Anika Therapeutics Inc. (ANIK - Free Report) , Cambrex Corporation (CBM - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) , all of which sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Anika Therapeutics represents a strong long-term expected growth rate of 15.00%. Notably, the company has a positive one-year return of almost 8.5%.
Cambrex Corporation has a positive one-year return of 5.4%. The company also has a promising long-term expected growth rate of 15.00%.
IDEXX Laboratories represents a stellar one-year return of 61.8%. The company has a long-term expected growth rate of almost 14.96%.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>